Casein kinase I epsilon interacts with mitochondrial proteins for the growth and survival of human ovarian cancer cells
0301 basic medicine
Medicine (General)
Biomedical and clinical sciences
Casein Kinase 1 epsilon
Cell Survival
casein kinase I epsilon
Mice, Nude
QH426-470
Mitochondrial Proteins
Mice
03 medical and health sciences
R5-920
Cell Line, Tumor
Protein Interaction Mapping
Genetics
Animals
Humans
Wnt signalling
Research Articles
Cell Proliferation
Ovarian Neoplasms
therapeutic target
Adenine Nucleotide Translocator 2
Epithelial Cells
Survival Analysis
3. Good health
mitochondria
Biological sciences
ovarian cancer
Female
Protein Binding
DOI:
10.1002/emmm.201101094
Publication Date:
2012-06-18T08:45:59Z
AUTHORS (13)
ABSTRACT
AbstractEpithelial ovarian cancer is the leading cause of death among gynaecologic cancers in Western countries. Our studies have shown that casein kinase I‐epsilon (CKIε), a Wnt pathway protein, is significantly overexpressed in ovarian cancer tissues and is associated with poor survival. Ectopic expression of CKIε in normal human ovarian surface epithelial cells and inhibition of CKIε in ovarian cancer cells and in xenografts demonstrated the importance of CKIε in regulating cell proliferation and migration. Interestingly, CKIε function did not seem to involve β‐catenin activity. Instead, CKIε was found to interact with several mitochondrial proteins including adenine nucleotide translocase 2 (ANT2). Inhibition of CKIε in ovarian cancer cells resulted in suppression of ANT2, downregulation of cellular ATP and the resulting cancer cells were more susceptible to chemotherapy. Our studies indicate that, in the context of ovarian cancer, the interaction between CKIε and ANT2 mediates pathogenic signalling that is distinct from the canonical Wnt/β‐catenin pathway and is essential for cell proliferation and is clinically associated with poor survival.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (47)
CITATIONS (52)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....